China Pharma Holdings (CPHI) Income towards Parent Company (2010 - 2026)
China Pharma Holdings (CPHI) reported Income towards Parent Company of -$1.1 million for Q1 2026, down 45.52% on a YoY basis from -$2.1 million in Q1 2025, and up 6.46% quarter-over-quarter from -$1.2 million in Q4 2025.
China Pharma Holdings (CPHI) Income towards Parent Company (2010 - 2026) Analysis & Trends
China Pharma Holdings has reported Income towards Parent Company for 17 years, with the latest figure at -$1.1 million in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company fell 45.52% year-over-year to -$1.1 million; the trailing twelve-month figure through Mar 2026 stood at -$3.5 million (up 22.36% YoY), and the FY2025 full-year result was -$3.2 million, up 32.7% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$1.1 million, up from -$1.2 million in the prior quarter.
- The five-year high for Income towards Parent Company was -$475976.0 in Q1 2023, with the low at -$1.4 million in Q2 2024.
- Historically, Income towards Parent Company has averaged -$948160.5 across 5 years, with a median of -$955892.0 in 2024.
- Annual changes were most pronounced in 2024 — Income towards Parent Company plunged 142.51% — and 2025, when it jumped 63.26%.
- China Pharma Holdings' Income towards Parent Company stood at -$1.3 million in 2022, then climbed by 2.53% to -$1.2 million in 2023, then increased by 0.63% to -$1.2 million in 2024, then grew by 0.19% to -$1.2 million in 2025, then gained by 6.46% to -$1.1 million in 2026.
- The last three Income towards Parent Company figures came in at -$1.1 million (Q1 2026), -$1.2 million (Q4 2025), and -$651482.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | China Pharma Holdings | 18.87 Mn | 18.70 Mn | 285,487.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.14 Mn |
| Dec 31, 2025 | -1.22 Mn |
| Sep 30, 2025 | -651,482.00 |
| Jun 30, 2025 | -528,367.00 |
| Mar 31, 2025 | -785,572.00 |
| Dec 31, 2024 | -1.22 Mn |
| Sep 30, 2024 | -1.12 Mn |
| Jun 30, 2024 | -1.44 Mn |
| Mar 31, 2024 | -955,892.00 |
| Dec 31, 2023 | -1.23 Mn |
| Sep 30, 2023 | -777,600.00 |
| Jun 30, 2023 | -593,029.00 |
| Mar 31, 2023 | -475,976.00 |
| Dec 31, 2022 | -1.26 Mn |
| Sep 30, 2022 | -790,773.00 |
| Jun 30, 2022 | -888,394.00 |
| Mar 31, 2022 | -1.03 Mn |
| Dec 31, 2021 | -980,719.00 |
| Sep 30, 2021 | -826,669.00 |
| Jun 30, 2021 | -824,761.00 |